Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Variation in the extent to which patient information leaflets describe potential benefits and harms of trial interventions: a commentary

Howick, Jeremy, Lantos, John D., Treweek, Shaun, Svobodova, Martina ORCID: https://orcid.org/0000-0001-7949-4039, Jacob, Nina, Edwards, Adrian ORCID: https://orcid.org/0000-0002-6228-4446, Bostock, Jennifer, Bower, Peter, Gillies, Katie and Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631 2025. Variation in the extent to which patient information leaflets describe potential benefits and harms of trial interventions: a commentary. Trials 26 (1) , 132. 10.1186/s13063-025-08824-8

[thumbnail of s13063-025-08824-8.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (809kB)

Abstract

Clinical trial participants must understand the possible risks and benefits of trial interventions before providing their informed consent to participate. The aim of this commentary is twofold: to summarize the discrepancies in the extent to which patient information leaflets (PILs) list potential benefits and harms of trial interventions; and to highlight subsequent ethical issues that may result from failure to disclose potential benefits or harms . A review of 247 patient information leaflets (PILs) found that the extent to which potential benefits and harms are described varies, with 28 (11%) not describing potential benefits and 23 (9%) not describing potential harms. We argue that there is no principled difference between potential benefits and potential harms (what is helpful for one person could harm another), and the need to disclose potential benefits may be less accepted than the need to disclose all potential harms. Additionally, while it is recognized that failure to mention potential harms may violate the ethical principle of autonomy, it is less well-established that other ethical principles, (the need to avoid harm (non-maleficence) , to help patients (beneficence), and to promote justice) may also be at risk when all potential harms and benefits are not  disclosed within PILs. We suggest that the way potential benefits and harms are described within PILs be harmonized according to recently established principles. [Abstract copyright: © 2025. The Author(s).]

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Schools > Medicine
Research Institutes & Centres > Centre for Trials Research (CNTRR)
Publisher: BioMed Central
Date of First Compliant Deposit: 7 May 2025
Date of Acceptance: 23 March 2025
Last Modified: 07 May 2025 10:15
URI: https://orca.cardiff.ac.uk/id/eprint/178116

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics